Last updated: 3 months ago
Replimune Group Q4 2024 Financial Report: Hold Recommendation Amidst Losses
Explore Replimune Group, Inc.'s Q4 2024 financial report. Key insights on losses, cash management, and clinical trial outcomes suggest a 'Hold' stock recommendation.